Search

Ned Weinshenker Phones & Addresses

  • 125 Buckingham Dr, Providence, UT 84332 (435) 752-1857
  • 2088 Sierra Ridge Ct, Salt Lake City, UT 84109 (801) 466-7336
  • 505 16Th Ave, Salt Lake City, UT 84103
  • Morgan, UT
  • Palo Alto, CA
  • 416 Cobblestone, Providence, UT 84332

Work

Company: Churchill oaks consulting Feb 2012 to Jun 2013 Address: Providence Ut Position: President

Education

Degree: Postdoctoral Fellow School / High School: Harvard University 1968 to 1969 Specialities: Organic Chemistry

Skills

Commercialization • Entrepreneurship • Strategy • Start-ups • Business Development • Chemistry • Biotechnology • Technology Transfer • Research • Patents • Business Strategy • Venture Capital • Licensing • Drug Discovery • Lifesciences • Intellectual Property • Molecular Biology • Patent Prosecution

Industries

Pharmaceuticals

Resumes

Resumes

Ned Weinshenker Photo 1

Ned Weinshenker

View page
Position:
President at Churchill Oaks Consulting, Director at Veritract, Director at Dynamic Screening Solutions, President at Cache Entrepreneurial Council, Director at JSK Therapeutics
Location:
Providence, Utah
Industry:
Pharmaceuticals
Work:
Churchill Oaks Consulting - Providence Ut since Feb 2012
President

Veritract since 2011
Director

Dynamic Screening Solutions - Logan, UT since 2011
Director

Cache Entrepreneurial Council - Cache Valley Utah since Jul 2009
President

JSK Therapeutics since 2008
Director
Education:
Harvard University 1968 - 1969
Postdoctoral Fellow, Organic Chemistry
Massachusetts Institute of Technology 1964 - 1968
Ph.D., Organic Chemistry
Polytechnic University 1960 - 1964
Bachelor of Science (BSc), Chemistry
Skills:
Commercialization
Entrepreneurship
Strategy
Start-ups
Business Development
Chemistry
Biotechnology
Technology Transfer
Research
Patents
Business Strategy
Venture Capital
Licensing
Drug Discovery
Lifesciences
Intellectual Property
Molecular Biology
Patent Prosecution

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ned M. Weinshenker
Director
Dynamic Screening Solutions, Inc
2125 Cyn Rdg Dr, Logan, UT 84341
1145 N 1600 E, Logan, UT 84341
1931 W Melrose St, Chicago, IL 60657
1360 N 1600 E, Logan, UT 84341

Publications

Us Patents

Cobalamin Conjugates For Anti-Tumor Therapy

View page
US Patent:
7232805, Jun 19, 2007
Filed:
Sep 10, 2003
Appl. No.:
10/659501
Inventors:
Ned M. Weinshenker - Salt Lake City UT,
Frederick G. West - Edmonton,
Barbara A. Araneo - Salt Lake City UT,
Weiping Li - Salt Lake City UT,
Assignee:
Inflabloc Pharmaceuticals, Inc. - Salt Lake City UT
International Classification:
A01N 43/04
A61K 31/70
C07G 3/00
C07G 11/00
C07H 15/00
C07H 17/00
US Classification:
514 33, 514 2, 514 6, 514 25, 514 35, 514 43, 514 52
Abstract:
The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an anti-tumor drug via a cleavable linker and one or more optional spacers. Cobalamin is covalently bound to a first spacer or the cleavable linker via the 5′-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells.

Dehydroepiandrosterone (Dhea) Congeners For Prevention And/Or Treatment Of Ulcers

View page
US Patent:
20040121991, Jun 24, 2004
Filed:
May 22, 2003
Appl. No.:
10/442988
Inventors:
Barbara Araneo - Salt Lake City UT,
Ned Weinshenker - Salt Lake City UT,
John Gebhard - Salt Lake City UT,
International Classification:
A61K031/56
US Classification:
514/169000
Abstract:
The present invention is related to acute therapeutic uses of dehydroepiandrosterone (DHEA) congeners. These uses include methods for treating or preventing ulcers which comprise administering to a subject either at risk or in need thereof having an ulcer a therapeutic amount of DHEA congener.
Ned M Weinshenker from Providence, UT, age ~79 Get Report